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ABSTRACT  
Chlamydia trachomatis (CT) elementary body (EB) ELISA was used to 
investigate serum anti-CT IgG1 (long-lived response) and IgG3 (short-lived 
response indicating more recent infection) from treatment (enrollment) and 6-
month follow-up visits in 77 women previously classified as having spontaneous 
resolution of chlamydia. 71.4% of women were IgG1+IgG3+, consistent with 
more recent chlamydia resolution. 15.6% were IgG3- at both visits, suggesting 
absence of recent chlamydia. Using EB ELISA, we demonstrated about one in 
six women classified as having spontaneous resolution of chlamydia might have 
been exposed to CT but not infected. Further, we classified their possible 
infection stage.        
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BACKGROUND 
Persisting genital Chlamydia trachomatis (CT) infection can lead to chronic 
inflammation, which may result in pelvic inflammatory disease and tubal factor 
infertility. Studying the natural clearance of CT infection in humans is ethically 
challenging because CT detection obligates treatment to eradicate infection and 
limit complications. Sparse studies that tested stored specimens suggest that 
~50% of CT infections spontaneously resolve (without treatment) within one year, 
presumably through immune-mediated clearance [1, 2]. Most studies on 
spontaneous resolution of CT infection have reported the resolution frequency 
between the time of CT screening (typically with a nucleic acid amplification test 
[NAAT]) and returning for follow-up, usually for treatment of a positive test. Those 
with a positive CT screening test but negative CT test at follow-up are classified 
as having spontaneous resolution, which studies report occurs in 11% to 44% of 
individuals within a few weeks to several months of a positive screening CT 
NAAT [3]. We found a spontaneous resolution frequency of ~20% in subjects 
studied at a STD Clinic in Birmingham, AL [4].  
The potential clinical significance of spontaneous resolution is that patients 
who clear CT infection before treatment have a lower reinfection risk than those 
with persisting infection [5]. It has been suggested this may be because patients 
whose infections spontaneously resolve develop protective immunity, in contrast 
to those with persisting infection having “arrested” immunity if treated too early in 
their infection [6]. However, some patients classified as spontaneous resolution 
based on a repeat NAAT being negative may have been misclassified. NAAT 
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detects nucleic acids and cannot distinguish viable from nonviable organisms. 
Thus, NAAT cannot differentiate established infection from exposure (i.e., from 
CT in a partner’s secretions) that does not lead to infection. In contrast, culture 
only detects viable organisms and was used to define spontaneous resolution in 
sparse studies [7, 8], but is less sensitive than NAAT and not widely available. 
Neither NAAT nor culture, if positive, provides information on potential 
timing/duration of the recently resolved CT infection; some infections could be 
“acute” (early stage of infection) or “primary” (an individual’s first CT infection). 
Neither test can identify a “remote” infection (in the distant past; likely years ago).  
We previously used a CT elementary body (EB) ELISA to characterize CT-
specific immunoglobulin (Ig) responses in individuals with a positive CT NAAT 
and found that IgG1 and IgG3 comprised the predominant serum anti-CT Ig 
response [9]. Among IgG subclasses, IgG1 has the longest half-life and is most 
abundant [10], whereas IgG3 is of lower abundance with a shorter half-life. IgG3, 
however, is the first IgG subclass to increase following infection and is 
associated with effector functions, including antibody dependent cell-mediated 
cytotoxicity and neutralization [10]. In this study, we used EB ELISA to measure 
anti-CT IgG1 and IgG3 responses in women previously classified as having 
spontaneous resolution of CT infection to address the following objectives: 1) 
distinguish true spontaneous resolution vs. CT exposure without established 
infection, and 2) delineate differences in timing/duration of CT infection by 
measuring differences in duration of anti-CT IgG1 and IgG3 responses [10], 
including measurements at a 6-month follow-up visit to assess for 
Ac
ce
pt
ed
 M
an
us
cr
ipt
 6 
seroconversion after treatment.  
 
METHODS 
Study Participants and Clinical Procedures 
Our study evaluated sera and clinical data previously collected from women 
returning to the Jefferson County Department of Health (JCDH) STD clinic in 
Birmingham, AL for treatment of a recent positive screening CT NAAT who were 
enrolled into a CT natural history study. Investigations focus on women classified 
as having spontaneous resolution of CT infection based on a negative repeat CT 
NAAT at enrollment, at which time women were interviewed regarding their 
medical and sexual history, underwent phlebotomy, had a cervical swab 
collected for repeat CT NAAT (Hologic Aptima Combo 2 [AC2]; Hologic, Inc., 
Marlborough, MA), and were treated with azithromycin 1g.  Participants had a 6-
month follow-up visit scheduled. Written informed consent was obtained from 
patients before enrollment. The study was approved by the University of 
Alabama at Birmingham Institutional Review Board (IRB) and JCDH. The 
Centers for Disease Control and Prevention (CDC) determined that CDC 
involvement did not constitute engagement in human subjects research, and 
CDC IRB review was therefore not required.    
 
CT EB-ELISA 
CT-specific IgG1 and IgG3 responses were measured by EB ELISA as described 
previously [9, 11, 12]. Briefly, ELISA was performed using formalin-fixed CT EBs 
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pooled from serovars D, F and J. IgG1 and IgG3 responses were detected using 
alkaline phosphatase-labeled mouse anti-human IgG1 (a pool of clones 4E3, 
Southern Biotech; and HP6069; Cal Biochem) and mouse anti-human IgG3 
(clone HP6050; Southern Biotech) at an optical density of 405 nm (OD405). The 
cutoff OD405 values for positive IgG1 and IgG3 anti-CT responses were >0.35 
and >0.1, respectively. Each subject’s serum was run in triplicates at a 1:32 
dilution. 
 
Statistical Analysis 
Differences in EB ELISA IgG1 and IgG3 OD405 readings from treatment (i.e., 
enrollment) to follow-up visits for women categorized into different CT infection 
groups (described in the results below) were analyzed with SAS 9.3 (SAS 
Institute, Cary, NC) using the Wilcoxon signed rank test. Differences in OD405 
readings between groups were analyzed using the Wilcoxon rank sum test. Only 
groups with ≥5 women were analyzed.  
 
RESULTS  
Frequency of IgG1 and IgG3 Seropositivity in Women Identified as 
having Spontaneous Resolution of CT Infection 
Of 108 women identified with spontaneous resolution of CT infection, 77 had 
serum for serological testing from both treatment and follow-up visits. The 
median age was 24 years (range 16-41) and 94.0% were non-Hispanic African 
Americans. The median interval between CT screening and treatment visits was 
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13 days (range 4-45) and between treatment and follow-up visits was 184 days 
(range 38-315). At the treatment visit, 74 (96.1%) women were seropositive for 
IgG1, 65 (84.4%) for IgG3, and 74 (96.1%) for IgG1 and/or IgG3. At the follow-up 
visit, 71 (92.2%) subjects were seropositive for IgG1, 61 (79.2%) for IgG3, and 
73 (94.8%) for IgG1 and/or IgG3.  
 
Using Anti-CT IgG3 Seropositivity Status to More Accurately Classify 
Spontaneous Resolution of CT infection  
IgG3 is the first IgG subclass to increase upon infection [10], therefore, it would 
be expected that most CT-infected individuals would be IgG3 seropositive. 
However, a small proportion of women could be initially IgG3 seronegative if the 
infection was acute and, in that instance, they would be expected to seroconvert 
within a few weeks. Of 77 subjects classified as having spontaneous resolution, 
15 (19.5%) were IgG3 seronegative at the treatment visit; 3 seroconverted IgG3 
at follow-up while the other 12 remained IgG3 seronegative. Thus, the positive 
CT NAAT at the screening visit in 12 (15.6%) subjects classified as having 
spontaneous resolution of CT infection may reflect an exposure to CT without an 
established CT infection.  
 
Evaluating Combinations of Anti-CT IgG1 and IgG3 Serostatus to Predict 
Timing/Duration of CT infection 
As previously discussed, IgG1 and IgG3 differ in response time and half-life [10], 
thus we assessed whether different IgG1 and IgG3 seropositive/seronegative 
Ac
ce
pt
ed
 M
an
us
cr
ipt
 9 
combinations from both visits could be used to predict timing/duration of CT 
infection. We created the following categories (participant groups) of 
timing/duration of CT infection based on expected differences in IgG1/IgG3 
serostatus: recent infection (IgG1+ and IgG3+ at the treatment visit; IgG3+ at the 
follow-up visit), primary infection (IgG1- at the treatment visit; seroconversion to 
IgG1+ at follow-up); acute infection (IgG3- at the treatment visit; seroconversion 
to IgG3+ at follow-up); remote infection (IgG1+ at the treatment visit; IgG3- at 
follow-up); and no infection (IgG1- and IgG3- at both treatment and follow-up 
visits). Table 1 summarizes results from our cohort. The majority, 57/77 (74.0%), 
were categorized as resolution of recent infection. 2 (2.6%) were categorized as 
resolving primary CT infection and 2 (2.6%) with resolution of acute infection. 13 
(16.9%) were categorized as having remote infection, meaning they likely had CT 
infection years ago but not recently. There were 3 women with no serological 
evidence of infection, suggesting despite CT antigen exposure (positive 
screening CT NAAT), they have never acquired CT infection. Our data highlight 
the heterogeneity in IgG1 and IgG3 responses that exists among women 
classified as having spontaneously resolution of CT infection.   
 
Effect of Predicted Timing/Duration of CT infection on Changes in IgG1 and 
IgG3 Responses between Treatment and Follow-up Visits.  
Illustrated in Figure 1, we analyzed the change in median OD405 IgG1 and IgG3 
anti-CT responses between treatment and follow-up visits to determine if the 
magnitude of the responses correlated with the categories of CT infection shown 
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in Table 1. Women resolving recent infection had a significant decrease in the 
OD405 for IgG3 from the treatment to follow-up visit (P = .010), but no significant 
change in OD405 for IgG1. The small number of women that resolved primary or 
acute CT infection had an increase in OD405 for both IgG1 and IgG3 at the follow-
up visit. The remote CT infection group had no significant change in the OD405 for 
both IgG1 and IgG3 responses between visits, and the CT-exposed women who 
never had infection also showed no noticeable change in the OD405 for IgG1 and 
IgG3 between visits. The recent infection group had a significantly higher OD405 
for IgG1 and IgG3 compared to those with remote infection (P<0.001 for both 
IgG1 and IgG3), possibly reflecting boosted antibody responses from recent CT 
exposure. Overall, changes in the median OD405 for IgG1 and IgG3 responses 
were consistent with those expected for the defined categories. 
 
DISCUSSION 
Our investigation of CT-specific IgG1 and IgG3 responses in women classified as 
having spontaneous resolution of CT infection contributed two main findings that 
advance our understanding of the natural history of CT infection: 1) some women 
classified as having spontaneous resolution based on CT NAAT results may 
have been misclassified and actually were exposed to CT but never infected; and 
2) among women who spontaneously resolved infection, there exists 
heterogeneity with respect to infection timing/duration.  
Persisting CT infection generally elicits CT-specific antibody responses. 
Failure to detect anti-CT antibody responses after sufficient follow-up in those 
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with a positive genital CT NAAT suggests either they lack the ability to generate 
antibody responses or were not infected, rather were only exposed. We found 
12/77 (15.6%) of women classified as spontaneous resolution never elicited an 
IgG3 response at treatment and follow-up visits: 9 of 12 were IgG1 positive, likely 
reflecting a remote CT infection and confirming their ability to mount anti-CT 
antibodies. However, 3 of 12 were never seropositive for either IgG1 or IgG3 at 
the treatment or follow-up visits, most likely because they were never infected 
and their positive screening CT NAAT may have reflected a CT exposure, 
although we cannot rule out infection with absence of antibody responses. The 
minimal change in IgG1 and IgG3 OD405 readings between treatment and follow-
up visits in these 12 women classified as having spontaneous resolution further 
supports absence of CT infection. This suggests one in six women were 
misclassified as having spontaneously resolved a CT infection. Women 
categorized in the recent infection group showed no change in IgG1 and a 
decline in IgG3 (Figure 1), which is in line with our published findings showing 
IgG3 responses, with a shorter half-life than IgG1, start to decline within 6 
months after infection eradication [9]. In contrast, women categorized with either 
primary or acute infection showed an increase in IgG1 and IgG3, reflecting 
detection of their infection at an earlier stage. With the lack of behavioral data in 
our study, we cannot exclude the possibility that subjects had re-exposures to CT 
that could have affected magnitude of antibody responses at follow-up.  
Overall, our findings demonstrate the importance of including anti-CT 
immunoglobulin measures with CT NAAT results for a more accurate study 
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classification of spontaneous resolution of CT infection. Our findings will pave the 
path for future studies related to the longevity of CT-specific immune responses 
in humans, which were previously not possible because of lack of sufficient 
knowledge about timing/duration of CT infection. Delineating primary vs. acute 
infection and remote vs. recent infection will be important in future studies 
investigating immune responses in individuals classified as having spontaneous 
resolution because presence vs. absence of recent infection and timing/duration 
of infection could affect immune response measures. 
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Figure 1. Effect of timing/duration of Chlamydia trachomatis (CT) 
infection on the change in the magnitude of anti-CT IgG1 and IgG3 
responses between treatment and follow-up visits. Line graph 
depicting the changes in the median OD405 of anti-CT IgG1 and IgG3 
responses detected by CT EB ELISA from a CT treatment visit (Tx) to a 
follow-up (FU) visit (on average ~6 months after treatment). Closed and 
open circles represent median OD405 value for IgG1 and IgG3 responses, 
respectively. The different infection timing/duration categories that were 
defined based upon seropositivity of IgG1 and IgG3 at Tx and FU visits 
are indicated on the x-axis. Dashed and dotted lines indicate the EB 
ELISA OD405 cutoff for IgG1 (0.35) and IgG3 (0.1), respectively. In the 
recent infection group, the magnitude of the IgG3 response significantly 
declined between the Tx and FU visits (median OD405 1.012 vs. 0.876; P = 
0.010), however there was no significant change in the IgG1 response 
median OD405 4.000 vs. 3.872 (P = 0.442). In the remote infection group, 
there was no significant change in the magnitude of the IgG1 or IgG3 
response between Tx and FU visits (IgG1: median OD405 0.798 vs. 0.936 
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[P = 0.735]; IgG3: median OD405 0.053 vs. 0.063 [P = 0.733]). The 
magnitude of the IgG1 and IgG3 responses were significantly higher at 
both the Tx and FU visits for the recent infection group vs. the remote 
infection group (all P values <0.001). Due to the small sample size in the 
acute, primary, and no infection groups (N<5 in each group), statistical 
analyses were only performed for the recent and remote infection groups.   
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Table 1. Classification of Chlamydia trachomatis (CT) infection based on 
different combinations of anti-CT IgG1 and IgG3 serostatus from women 
classified as having spontaneous resolution by NAAT. 
 
Type of Infection 
IgG subclass responses 
# Subjects (%) 
Treatment visit Follow-up visit 
Recenta 
IgG1+ IgG3+ IgG1- IgG3+ 2 (2.60) 
IgG1+ IgG3+ IgG1+ IgG3+ 55 (71.40) 
Primaryb 
IgG1- IgG3+ IgG1+ IgG3+ 1 (1.30) 
IgG1- IgG3- IgG1+ IgG3+ 1 (1.30) 
Acutec IgG1+ IgG3- IgG1+ IgG3+ 2 (2.60) 
 
Remoted 
 
IgG1+ IgG3+ IgG1- IgG3- 1 (1.30) 
IgG1+ IgG3+ IgG1+ IgG3- 3 (3.90) 
IgG1+ IgG3- IgG1+ IgG3- 9 (11.70) 
No Infection IgG1- IgG3- IgG1- IgG3- 3 (3.90) 
 
a Recently resolved CT infection. 
b An individual’s first CT infection 
c Early stage of infection 
d Individual was infected in the distant past (likely years ago) 
